FABRIC MASK MANUFACTURER P P N O N W O V E N M U L T I L A Y E R S • Meet regulatory requirements for the application • Provide technical support including specific color, processing and molding recommendations • Deliver a highly hydrophilic performance • Developed a compliant additives solution to meet necessary regulatory specifications • Provided technical expertise throughout the design and manufacturing process • Offered an effective solution to make it soft touch while hydrophilic Cesa Fiber Additives KEY REQUIREMENTS WHY AVIENT?

View PDF The SQS herewith attests that the organisation named below has a management system that meets the requirements of the normative base mentioned. 70 01 _1 /A pr il 20 22 /V er si on 2 .0 Certificate P.T.

Baby diaper manufactureR BABY DIAPER MANUFACTURER P P N O N W O V E N M U L T I L A Y E R S • Provide slip additives with high concentrated content • Offer products meeting customer FDA requirements • Shorten supply lead time and reduce cost compared with importing from EU • Offered additives with high concentrated content, which is unachievable for competitors • Provided regulatory support, significant cost and time savings • Compressed the timeline through on-site color visualization, exploration, and formulation of new colors by the expert designer Cesa Slip Additives KEY REQUIREMENTS WHY AVIENT?

Any form of discrimination in violation of the provisions of Title VII of the Civil Rights Act of 1964, as amended, Title I and Title V of the Americans with Disabilities Act of 1990, as amended, The Age Discrimination in Employment Act of 1967, as amended, and/or Title II of the Genetic Information Nondiscrimination Act of 2008, or this policy is against the interests of Avient and its employees and will not be permitted.

Any form of discrimination in violation of the provisions of Title VII of the Civil Rights Act of 1964, as amended, Title I and Title V of the Americans with Disabilities Act of 1990, as amended, The Age Discrimination in Employment Act of 1967, as amended, and/or Title II of the Genetic Information Nondiscrimination Act of 2008, or this policy is against the interests of Avient and its employees and will not be permitted.

SEMICONDUCTOR PACKAGING OEM S P E C I A L T Y , S T A T I C D I S S I P A T I V E P A C K A G I N G • Provide protection against electrostatic discharge (ESD) and environmental variations • Ensure highly specialized, clean manufacturing conditions • Deliver stringent quality control of ionic and metal contamination • Maintain availability of raw materials across a global supply chain • Ability to translate production globally • Protected critical electronics from ESD while providing an environmental barrier • Adhered to strict quality and cleanliness controls from raw material handling through production to help maintain high-purity standards, such as ultra-clean feeders, deionized water, and specific HVAC systems, supporting quality initiatives, including PCS reviews, eCoA, and HA assessments • Exceeded customer expectations for controlling ionic and metal contamination down to parts per billion (PPB) • Offered global capabilities with local support and material supply to meet growing semiconductor industry needs Stat-Tech Static Dissipative Formulations KEY REQUIREMENTS WHY AVIENT?

Sous réserve de ce qui précède, et à moins qu'il n'en soit expressément stipulé autrement, le Vendeur ne fait aucune déclaration ni ne consent de garantie, de quelque nature que ce soit, expresse ou tacite, quant à la qualité marchande du Produit ou son adéquation à un objectif spécifique. Dans le cas d'une Force Majeure, le Vendeur ne sera pas tenu d'acheter des marchandises auprès de tiers pour les revendre à l 'Acheteur, ni de compenser une quelconque augmentation de coûts supportée par l'Acheteur du fait de l'achat de marchandises de substitution auprès d'un tiers. 14.

D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi en t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x SUMMARY: WHY INVEST IN AVIENT?

Microsoft PowerPoint - AVNT June IR Conferences_6.1.2023 1130AM AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) J U N E 2 0 2 3 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 37 79 89 83 81 76 73 90 82 77 76 74 70 58 22 A vi en t K W R P P G F U L A V Y R P M F M C C E H X L A S H E C L H U N E M N S C L MULTIPLE EXPANSION Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of May 31, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $36.50. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 38 EV / 2023E EBITDA Historic Multiple 6.5 8.3 9.6 13.2 13.0 12.8 11.3 8.6 17.9 16.8 10.7 8.8 8.8 8.7 7.5 6.9 A vi en t (2 01 1) A vi en t (2 01 8) A vi en t (2 02 3) K W R P P G R P M A V Y F U L E C L H X L F M C S C L C E A S H E M N H U N Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) AU G U S T 2 0 2 3 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. GUIDANCE (TOTAL COMPANY) 12 15.4% 15.9% Guidance Actual Adjusted EBITDA Margin % Better-than-expected margins driven by: • Favorable mix - strong demand for composite applications • Raw material deflation Q2 EBITDA BRIDGE (TOTAL COMPANY) 13 ($ millions) CAI: Price / Mix 7) Deflation 11) SEM: Price / Mix 2) Deflation 6) Net Price Benefit 26) Wage and Energy Inflation (10) Cost Reductions 13) FX (2) Q2 2023 Actual $131) Adjusted EBITDA Q2 2022 Pro Forma $ 172) Demand (68) • Demand conditions vs. expectations: US & Canada LATAM EMEA Asia • Net price benefit remains greater than wage and energy inflation • Clariant synergies and reduced administrative costs Q2 2023 SEQUENTIAL SALES BY REGION Q 2 2 0 2 3 v s . Avient reflects 2023 adjusted EBITDA guidance of $525M and estimated run-rate CAPEX of $110M. 2023E (%) 27 79 89 83 83 78 75 90 81 76 72 68 63 53 11 A vi en t K W R F U L P P G A V Y R P M F M C C E E C L A S H H X L H U N E M N S C L Avient Specialty Formulators Other Specialty / Chemical Companies MULTIPLE EXPANSION Source: Peer data per Bloomberg as of August 17, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $525M and closing share price of $37.07.